Sho ichi Yamagishi

Summary

Affiliation: Kurume University School of Medicine
Country: Japan

Publications

  1. doi request reprint Potential clinical utility of advanced glycation end product cross-link breakers in age- and diabetes-associated disorders
    Sho ichi Yamagishi
    Department of Pathophysiology and Therapeutics of Diabetic Vascular Complications, Kurume University School of Medicine, Kurume 830 0011, Japan
    Rejuvenation Res 15:564-72. 2012
  2. ncbi request reprint Pigment epithelium-derived factor protects cultured retinal pericytes from advanced glycation end product-induced injury through its antioxidative properties
    Sho ichi Yamagishi
    Division of Endocrinology and Metabolism, Department of Medicine, Kurume University School of Medicine, Kurume 830 0011, Japan
    Biochem Biophys Res Commun 296:877-82. 2002
  3. ncbi request reprint Inhibition of intestinal cholesterol absorption by ezetimibe is a novel therapeutic target for fatty liver
    S Yamagishi
    Department of Internal Medicine, Kurume University School of Medicine, 67 Asahi Machi, Kurume 830 0011, Japan
    Med Hypotheses 66:844-6. 2006
  4. ncbi request reprint Molecular mechanism for accelerated atherosclerosis in diabetes and its potential therapeutic intervention
    S Yamagishi
    Department of Internal Medicine III, Kurume University School of Medicine, Kurume, Japan
    Int J Clin Pharmacol Res 24:129-34. 2004
  5. ncbi request reprint Advanced glycation end products (AGEs) and diabetic vascular complications
    Sho ichi Yamagishi
    Department of Internal Medicine III, Kurume University School of Medicine, Kurume 830 0011, Japan
    Curr Diabetes Rev 1:93-106. 2005
  6. ncbi request reprint Soluble form of a receptor for advanced glycation end products (sRAGE) as a biomarker
    Sho ichi Yamagishi
    Department of Pathophysiology and Therapeutics of Diabetic Vascular Complications, Kurume University School of Medicine, Fukuoka, Japan
    Front Biosci (Elite Ed) 2:1184-95. 2010
  7. doi request reprint Pigment epithelium-derived factor (PEDF) prevents platelet activation and aggregation in diabetic rats by blocking deleterious effects of advanced glycation end products (AGEs)
    Sho ichi Yamagishi
    Department of Pathophysiology and Therapeutics of Diabetic Vascular Complications, Kurume University School of Medicine, Kurume, Japan
    Diabetes Metab Res Rev 25:266-71. 2009
  8. ncbi request reprint Telmisartan inhibits advanced glycation end products (AGEs)-elicited endothelial cell injury by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-gammaactivation
    Sho ichi Yamagishi
    Department of Medicine, Kurume University School of Medicine, Kurume, Japan
    Protein Pept Lett 15:850-3. 2008
  9. ncbi request reprint Therapeutic potentials of unicellular green alga Chlorella in advanced glycation end product (AGE)-related disorders
    S Yamagishi
    Department of Medicine, School of Medicine, Kurume University, 67 Asahi Machi, Kurume 830 0011, Japan
    Med Hypotheses 65:953-5. 2005
  10. ncbi request reprint Pigment epithelium-derived factor (PEDF) blocks advanced glycation end product (AGE)-induced angiogenesis in vitro
    S I Yamagishi
    Department of Internal Medicine, Kurume University School of Medicine, Kurume, Japan
    Horm Metab Res 39:233-5. 2007

Collaborators

Detail Information

Publications165 found, 100 shown here

  1. doi request reprint Potential clinical utility of advanced glycation end product cross-link breakers in age- and diabetes-associated disorders
    Sho ichi Yamagishi
    Department of Pathophysiology and Therapeutics of Diabetic Vascular Complications, Kurume University School of Medicine, Kurume 830 0011, Japan
    Rejuvenation Res 15:564-72. 2012
    ..This article summarizes the potential clinical utility of AGE cross-link breakers in the prevention and management of age- and diabetes-associated disorders...
  2. ncbi request reprint Pigment epithelium-derived factor protects cultured retinal pericytes from advanced glycation end product-induced injury through its antioxidative properties
    Sho ichi Yamagishi
    Division of Endocrinology and Metabolism, Department of Medicine, Kurume University School of Medicine, Kurume 830 0011, Japan
    Biochem Biophys Res Commun 296:877-82. 2002
    ..Our present study suggests that substitution of PEDF proteins may be a promising strategy in treatment of patients with early diabetic retinopathy...
  3. ncbi request reprint Inhibition of intestinal cholesterol absorption by ezetimibe is a novel therapeutic target for fatty liver
    S Yamagishi
    Department of Internal Medicine, Kurume University School of Medicine, 67 Asahi Machi, Kurume 830 0011, Japan
    Med Hypotheses 66:844-6. 2006
    ....
  4. ncbi request reprint Molecular mechanism for accelerated atherosclerosis in diabetes and its potential therapeutic intervention
    S Yamagishi
    Department of Internal Medicine III, Kurume University School of Medicine, Kurume, Japan
    Int J Clin Pharmacol Res 24:129-34. 2004
    ..In this review, we discuss the molecular mechanisms for accelerated atherosclerosis in diabetes and the potential therapeutic interventions, especially focusing on postprandial hyperglycemia and advanced glycation end products (AGEs)...
  5. ncbi request reprint Advanced glycation end products (AGEs) and diabetic vascular complications
    Sho ichi Yamagishi
    Department of Internal Medicine III, Kurume University School of Medicine, Kurume 830 0011, Japan
    Curr Diabetes Rev 1:93-106. 2005
    ..Several types of AGE inhibitors and their therapeutic implications in this devastating disorder are also discussed here...
  6. ncbi request reprint Soluble form of a receptor for advanced glycation end products (sRAGE) as a biomarker
    Sho ichi Yamagishi
    Department of Pathophysiology and Therapeutics of Diabetic Vascular Complications, Kurume University School of Medicine, Fukuoka, Japan
    Front Biosci (Elite Ed) 2:1184-95. 2010
    ..Therefore, in this paper, we review the kinetics, regulation and pathophysiological role of sRAGE in humans. We further discuss the potential clinical utility of measuring sRAGE in various disorders as a biomarker...
  7. doi request reprint Pigment epithelium-derived factor (PEDF) prevents platelet activation and aggregation in diabetic rats by blocking deleterious effects of advanced glycation end products (AGEs)
    Sho ichi Yamagishi
    Department of Pathophysiology and Therapeutics of Diabetic Vascular Complications, Kurume University School of Medicine, Kurume, Japan
    Diabetes Metab Res Rev 25:266-71. 2009
    ....
  8. ncbi request reprint Telmisartan inhibits advanced glycation end products (AGEs)-elicited endothelial cell injury by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-gammaactivation
    Sho ichi Yamagishi
    Department of Medicine, Kurume University School of Medicine, Kurume, Japan
    Protein Pept Lett 15:850-3. 2008
    ..Our present study provides a unique beneficial aspect of telmisartan. Specifically, it could work as an anti-inflammatory agent against AGEs via PPAR-gamma activation and may play a protective role against diabetic microangiopathy...
  9. ncbi request reprint Therapeutic potentials of unicellular green alga Chlorella in advanced glycation end product (AGE)-related disorders
    S Yamagishi
    Department of Medicine, School of Medicine, Kurume University, 67 Asahi Machi, Kurume 830 0011, Japan
    Med Hypotheses 65:953-5. 2005
    ....
  10. ncbi request reprint Pigment epithelium-derived factor (PEDF) blocks advanced glycation end product (AGE)-induced angiogenesis in vitro
    S I Yamagishi
    Department of Internal Medicine, Kurume University School of Medicine, Kurume, Japan
    Horm Metab Res 39:233-5. 2007
  11. ncbi request reprint Olmesartan blocks advanced glycation end products (AGEs)-induced angiogenesis in vitro by suppressing receptor for AGEs (RAGE) expression
    Sho ichi Yamagishi
    Department of Medicine, Kurume University School of Medicine, 67 Asahi Machi, Kurume 830 0011, Japan
    Microvasc Res 75:130-4. 2008
    ..Our present study suggests that blockade of the renin-angiotensin system by olmesartan may play a protective role against PDR by attenuating the deleterious effects of AGEs via down-regulation of RAGE...
  12. pmc Minodronate, a newly developed nitrogen-containing bisphosphonate, suppresses melanoma growth and improves survival in nude mice by blocking vascular endothelial growth factor signaling
    Sho ichi Yamagishi
    Department of Internal Medicine III, Kurume University School of Medicine, 67 Asahi Machi, Kurume 830 0011, Japan
    Am J Pathol 165:1865-74. 2004
    ..The present study provides a novel potential therapeutic strategy for the treatment of melanoma...
  13. ncbi request reprint Renoprotective effects of azelnidipine, a dihydropyridine-based calcium antagonist in advanced glycation end product (AGE)-injected rats
    S Yamagishi
    Department of Medicine, Kurume University School of Medicine, Japan
    Int J Tissue React 27:137-43. 2005
    ..Our present study suggests that azelnidipine would represent a valuable drug for the treatment of diabetic nephropathy by blocking the deleterious effects of AGEs...
  14. ncbi request reprint Olmesartan blocks inflammatory reactions in endothelial cells evoked by advanced glycation end products by suppressing generation of reactive oxygen species
    Sho ichi Yamagishi
    Division of Cardiovascular Medicine, Department of Medicine, Kurume University School of Medicine, Kurume, Japan
    Ophthalmic Res 40:10-5. 2008
    ....
  15. ncbi request reprint Advanced glycation end products and receptor-oxidative stress system in diabetic vascular complications
    Sho ichi Yamagishi
    Department of Pathophysiology and Therapeutics of Diabetic Vascular Complications, Kurume University School of Medicine, Kurume, Japan
    Ther Apher Dial 13:534-9. 2009
    ..In this paper, we review the pathophysiological role of AGE-RAGE-oxidative stress system and its therapeutic interventions in diabetic micro- and macroangiopathy...
  16. doi request reprint Possible molecular mechanisms by which angiotensin II type 1 receptor blockers (ARBs) prevent the development of atrial fibrillation in insulin resistant patients
    S I Yamagishi
    Department of Medicine, Division of Cardiovascular Medicine, Kurume University School of Medicine, Kurume, Japan
    Horm Metab Res 40:640-4. 2008
    ....
  17. ncbi request reprint Pigment-epithelium-derived factor suppresses expression of receptor for advanced glycation end products in the eye of diabetic rats
    Sho ichi Yamagishi
    Department of Internal Medicine, Kurume University School of Medicine, Kurume, Japan
    Ophthalmic Res 39:92-7. 2007
    ..Our present study suggests that pharmacological upregulation or substitution of PEDF may play a protective role against diabetic retinopathy by attenuating the deleterious effect of AGEs...
  18. ncbi request reprint A novel pleiotropic effect of atorvastatin on advanced glycation end product (AGE)-related disorders
    S Yamagishi
    Department of Medicine, Kurume University School of Medicine, 67 Asahi Machi, Kurume 830 0011, Japan
    Med Hypotheses 69:338-40. 2007
    ....
  19. doi request reprint Low-density lipoprotein levels are one of the independent determinants of circulating levels of advanced glycation end products in nondiabetic subjects
    Sho ichi Yamagishi
    Department of Pathophysiology and Therapeutics of Diabetic Vascular Complications, Kurume University School of Medicine, Kurume, Japan
    Clin Cardiol 32:E12-5. 2009
    ..In this study, we investigated whether LDL-C levels are one of the independent determinants of circulating AGEs levels in a nondiabetic general population...
  20. doi request reprint Positive association of circulating levels of advanced glycation end products (AGEs) with pigment epithelium-derived factor (PEDF) in a general population
    Sho ichi Yamagishi
    Department of Pathophysiology and Therapeutics of Diabetic Vascular Complications, Kurume University School of Medicine, 67 Asahi Machi, Kurume 830 0011, Japan
    Pharmacol Res 61:103-7. 2010
    ..Adipose tissue and liver may be target organs for the AGE-induced PEDF overexpression in humans. Serum PEDF levels may be elevated in response to circulating AGEs as a counter-system against the AGE-elicited tissue damage...
  21. ncbi request reprint Pathophysiological role of pigment epithelium-derived factor (PEDF) in hepatic disorders
    S I Yamagishi
    Department of Pathophysiology and Therapeutics of Diabetic Vascular Complications, Kurume University, School of Medicine, Kurume 830 0011, Japan
    Curr Med Chem 17:1995-2000. 2010
    ....
  22. ncbi request reprint Role of asymmetric dimethylarginine (ADMA) in diabetic vascular complications
    Sho ichi Yamagishi
    Department of Pathophysiology and Therapeutics of Diabetic Vascular Complications, Kurume University School of Medicine, Kurume 830 0011, Japan
    Curr Pharm Des 14:2613-8. 2008
    ..In this paper, we review the pathophysiological role of ADMA and DDAH system for accelerated atherosclerosis in diabetes and the therapeutic utility of ADMA suppression in CVD in diabetes...
  23. ncbi request reprint Role of insulin-sensitizing property of telmisartan, a commercially available angiotensin II type 1 receptor blocker in preventing the development of atrial fibrillation
    S Yamagishi
    Department of Internal Medicine, Kurume University School of Medicine, 67 Asahi Machi, Kurume 830 0011, Japan
    Med Hypotheses 66:118-20. 2006
    ..This randomized, double-blind, multicenter international studies will provide further information whether telmisartan can improve insulin resistance and subsequently reduce the development of Af in high-risk hypertensive patients...
  24. ncbi request reprint Role of postprandial hyperglycaemia in cardiovascular disease in diabetes
    S I Yamagishi
    Department of Medicine, Division of Cardiovascular Medicine, Kurume University School of Medicine, Kurume, Japan
    Int J Clin Pract 61:83-7. 2007
    ..We also discuss here the potential therapeutic strategy that specifically targets CVD in patients with diabetes...
  25. ncbi request reprint Nifedipine inhibits tumor necrosis factor-alpha-induced monocyte chemoattractant protein-1 overexpression by blocking NADPH oxidase-mediated reactive oxygen species generation
    S Yamagishi
    Department of Medicine, Kurume University School of Medicine, Kurume, Japan
    Drugs Exp Clin Res 29:147-52. 2003
    ..Our present study suggests that nifedipine may play a protective role in the development and progression of atherosclerosis through its antioxidative properties...
  26. ncbi request reprint Olmesartan medoxomil, a newly developed angiotensin II type 1 receptor antagonist, protects against renal damage in advanced glycation end product (age)-injected rats
    S Yamagishi
    Department of Medicine, Kurume University School of Medicine, Kurume, Japan
    Drugs Exp Clin Res 31:45-51. 2005
    ..Our study suggests that olmesartan medoxomil could be a valuable drug for the treatment of diabetic nephropathy by blocking the deleterious effects of AGEs...
  27. ncbi request reprint Food-derived advanced glycation end products (AGEs): a novel therapeutic target for various disorders
    Sho ichi Yamagishi
    Division of Cardiovascular Medicine, Kurume University School of Medicine, Kurume 830 0011, Japan
    Curr Pharm Des 13:2832-6. 2007
    ..In this paper, we review the pathological role of food-derived AGEs in various types of disorders and discuss the potential utility of oral adsorbent that inhibits the absorption of AGEs in these devastating diseases...
  28. ncbi request reprint Inhibition of postprandial hyperglycemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrome
    S Yamagishi
    Department of Medicine, Kurume University School of Medicine, 67 Asahi Machi, Kurume 830 0011, Japan
    Med Hypotheses 65:152-4. 2005
    ....
  29. ncbi request reprint Blockade of the advanced glycation end products (AGEs) and their receptor (RAGE) system is a possible mechanism for sustained beneficial effects of multifactorial intervention on mortality in type 2 diabetes
    S Yamagishi
    Department of Pathophysiology and Therapeutics of Diabetic Vascular Complications, Kurume University School of Medicine, 67 Asahi Machi, Kurume 830 0011, Japan
    Med Hypotheses 71:749-51. 2008
    ..This clinical investigation may provide us more information about whether blockade of the AGE-RAGE system is one of the mechanisms for sustained beneficial effects of multifactorial intervention on mortality in type 2 diabetes...
  30. ncbi request reprint Nifedipine inhibits tumor necrosis factor-alpha-induced upregulation of monocyte chemoattractant protein-1 mRNA levels by suppressing CD40 expression in endothelial cells
    S Yamagishi
    Department of Medicine, Kurume University School of Medicine, Kurume, Japan
    Drugs Exp Clin Res 31:13-7. 2005
    ..Our present study suggests that blockade of CD40 signaling in endothelial cells may be a molecular target for the vasculoprotective property of nifedipine...
  31. ncbi request reprint Advanced glycation end products (AGEs) and cardiovascular disease (CVD) in diabetes
    Sho ichi Yamagishi
    Department of Medicine, Division of Cardiovascular Medicine, Kurume University School of Medicine, Kurume 830 0011, Japan
    Cardiovasc Hematol Agents Med Chem 5:236-40. 2007
    ....
  32. ncbi request reprint Atheroprotective properties of pigment epithelium-derived factor (PEDF) in cardiometabolic disorders
    Sho ichi Yamagishi
    Department of Pathophysiology and Therapeutics of Diabetic Vascular Complications, Kurume University School of Medicine, Kurume 830 0011, Japan
    Curr Pharm Des 15:1027-33. 2009
    ..We also discuss here the kinetics and regulation of PEDF in cardiometabolic disorders in humans...
  33. ncbi request reprint Pigment epithelium-derived factor Met72Thr polymorphism in patients with diabetic microangiopathy
    S Yamagishi
    Division of Endocrinology and Metabolism, Department of Medicine, Kurume University School of Medicine, Kurume, Japan
    Int J Clin Pharmacol Res 22:67-71. 2002
    ..These observations suggest that these genetic variants might not be involved in the mechanism of diabetic microangiopathy in patients with diabetes...
  34. ncbi request reprint Pleiotropic effects of nifedipine on atherosclerosis
    Sho ichi Yamagishi
    Department of Internal Medicine and Radioisotope Institute for Basic and Clinical Medicine, Kurume University School of Medicine, Kurume 830 0011, Japan
    Curr Pharm Des 12:1543-7. 2006
    ..In this review, we discuss the pleiotropic effects of nifedipine on atherosclerosis, especially focusing on its anti-oxidative properties...
  35. ncbi request reprint Atheroprotective properties of nifedipine
    S Yamagishi
    Department of Internal Medicine, Kurume University School of Medicine, Kurume, Japan
    Int J Tissue React 27:63-7. 2005
    ..In this review, we discuss the molecular mechanisms for the atheroprotective effects of nifedipine, with special emphasis on its anti-oxidative properties...
  36. ncbi request reprint Serum or cerebrospinal fluid levels of glyceraldehyde-derived advanced glycation end products (AGEs) may be a promising biomarker for early detection of Alzheimer's disease
    S Yamagishi
    Department of Medicine, Kurume University School of Medicine, 67 Asahi Machi, Kurume 830 0011, Japan
    Med Hypotheses 64:1205-7. 2005
    ....
  37. ncbi request reprint Pigment epithelium-derived factor (PEDF) and cardiometabolic disorders
    Sho ichi Yamagishi
    Department of Pathophysiology and Therapeutics of Diabetic Vascular Complications, Kurume University School of Medicine, Kurume 830 0011, Japan
    Curr Pharm Des 20:2377-86. 2014
    ..This paper discusses not only the role of PEDF, but also the clinical utility of measuring its levels in patients with various cardiometabolic disorders...
  38. pmc Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate/insulin-like growth factor II receptor
    Yuji Ishibashi
    Department of Pathophysiology and Therapeutics of Diabetic Vascular Complications, Kurume University School of Medicine, 67 Asahi Machi, Kurume, 830 0011, Japan
    Cardiovasc Diabetol 12:125. 2013
    ..Inhibition of dipeptidyl peptidase-4 (DPP-4) is a potential therapeutic target for type 2 diabetes. However, the role of DPP-4 in AGE-induced endothelial cell (EC) damage remains unclear...
  39. doi request reprint Administration of pigment epithelium-derived factor prolongs bleeding time by suppressing plasminogen activator inhibitor-1 activity and platelet aggregation in rats
    S Yamagishi
    Department of Pathophysiology and Therapeutics of Diabetic Vascular Complications, Kurume University School of Medicine, 67 Asahi Machi, Kurume, 830 0011, Japan
    Clin Exp Med 9:73-6. 2009
    ..PEDF may be a novel therapeutic target for the treatment of patients with thrombogenic tendency and hypercoagulability...
  40. ncbi request reprint Cardiovascular disease in diabetes
    Sho ichi Yamagishi
    Department of Internal Medicine III, Kurume University School of Medicine, Kurume, Japan
    Mini Rev Med Chem 6:313-8. 2006
    ..We also discuss here the potential therapeutic strategy that specifically targets CVD in patients with diabetes...
  41. ncbi request reprint Pigment epithelium-derived factor is a pericyte mitogen secreted by microvascular endothelial cells: possible participation of angiotensin II-elicited PEDF downregulation in diabetic retinopathy
    S Yamagishi
    Department of Medicine, Kurume University School of Medicine, Kurume, Japan
    Int J Tissue React 27:197-202. 2005
    ..Our present results suggest that PEDF is an EC-derived mitogen or survival factor for retinal pericytes. Suppression by Ang II of the EC-derived PEDF may be involved in exacerbation of diabetic retinopathy in patients with hypertension...
  42. ncbi request reprint Pigment epithelium-derived factor (PEDF) blocks angiotensin II-induced T cell proliferation by suppressing autocrine production of interleukin-2
    Sho ichi Yamagishi
    Department of Internal Medicine III, Kurume University School of Medicine, Japan
    Med Chem 2:265-9. 2006
    ..Blockade by PEDF of T cell activation may become a novel therapeutic target for atherosclerosis...
  43. ncbi request reprint Angiotensin II-type 1 receptor interaction upregulates vascular endothelial growth factor messenger RNA levels in retinal pericytes through intracellular reactive oxygen species generation
    S Yamagishi
    Division of Endocrinology and Metabolism, Department of Medicine, Kurume University School of Medicine, 67 Asahi Machi, Kurume 830 0011, Japan
    Drugs Exp Clin Res 29:75-80. 2003
    ..The present results suggest that Ang II-type 1 receptor interaction could induce pericyte loss and dysfunction through intracellular ROS generation, thus being involved in the development and progression of diabetic retinopathy...
  44. ncbi request reprint Pigment epithelium-derived factor (PEDF) blocks angiotensin II-induced T cell adhesion to endothelial cells by suppressing intercellular adhesion molecule-1
    S I Yamagishi
    Department of Internal Medicine III, Kurume University School of Medicine, Kurume, Japan
    Horm Metab Res 38:546-8. 2006
  45. ncbi request reprint Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property
    S Yamagishi
    Department of Medicine, Kurume University School of Medicine, Kurume, Japan
    Med Hypotheses 64:476-8. 2005
    ....
  46. ncbi request reprint Molecular mechanisms of diabetic nephropathy and its therapeutic intervention
    Sho ichi Yamagishi
    Department of Medicine, Division of Caridovascular Medicine, Kurume University School of Medicine, Kurume, Japan
    Curr Drug Targets 8:952-9. 2007
    ....
  47. ncbi request reprint Anti-atherothrombogenic properties of PEDF
    S I Yamagishi
    Department of Pathophysiology and Therapeutics of Diabetic Vascular Complications, Kurume University, School of Medicine, Kurume 830 0011, Japan
    Curr Mol Med 10:284-91. 2010
    ..This article summarizes the pathophysiological role of PEDF in atherothrombosis and its potential therapeutic implication in CVD. We also discuss here the kinetics and regulation of PEDF in high-risk patients for atherothrombosis...
  48. ncbi request reprint Pigment epithelium-derived factor (PEDF): its potential therapeutic implication in diabetic vascular complications
    Sho ichi Yamagishi
    Department of Medicine, Division of Caridovascular Medicine, Kurume University School of Medicine, Kurume 830 0011, Japan
    Curr Drug Targets 9:1025-9. 2008
    ..This article summarizes the pathophysiological role of PEDF for vascular complication in diabetes and its potential therapeutic implication in this devastating disorder...
  49. ncbi request reprint Azelnidipine, a newly developed long-acting calcium antagonist, inhibits tumor necrosis factor-alpha-induced interleukin-8 expression in endothelial cells through its anti-oxidative properties
    Sho ichi Yamagishi
    Department of Internal Medicine III, Kurume University School of Medicine, Kurume, Japan
    J Cardiovasc Pharmacol 43:724-30. 2004
    ..Our present study suggests that azelnidipine may play a protective role in the development and progression of atherosclerosis through its anti-oxidative properties...
  50. ncbi request reprint Pigment epithelium-derived factor (PEDF) blocks angiotensin II signaling in endothelial cells via suppression of NADPH oxidase: a novel anti-oxidative mechanism of PEDF
    Sho ichi Yamagishi
    Department of Internal Medicine III, Kurume University School of Medicine, 67 Asahi Machi, Kurume, 830 0011, Japan
    Cell Tissue Res 320:437-45. 2005
    ..These results demonstrate that PEDF inhibits Ang-II-induced EC activation by suppressing NADPH-oxidase-mediated ROS generation and that PEDF may play a protective role in the development and progression of atherosclerosis...
  51. ncbi request reprint Pigment epithelium-derived factor inhibits TNF-alpha-induced interleukin-6 expression in endothelial cells by suppressing NADPH oxidase-mediated reactive oxygen species generation
    Sho ichi Yamagishi
    Department of Internal Medicine III, Kurume University School of Medicine, Kurume 830 0011, Japan
    J Mol Cell Cardiol 37:497-506. 2004
    ..Our present study suggests that PEDF may play an important role in the development and progression of atherosclerosis...
  52. pmc Atorvastatin reduces proteinuria in non-diabetic chronic kidney disease patients partly via lowering serum levels of advanced glycation end products (AGEs)
    Tsukasa Nakamura
    Division of Nephrology, Department of Internal Medicine, Shinmatsudo Central General Hospital, Chiba, Japan
    Oxid Med Cell Longev 3:304-7. 2010
    ..Atorvastatin may have AGE-lowering effects in CKD patients as well that could contribute to renoprotective properties of this agent...
  53. pmc Efficacy of combination therapy with telmisartan plus amlodipine in patients with poorly controlled hypertension
    Hisatoshi Bekki
    ABC Trial Group, Kurume, Japan
    Oxid Med Cell Longev 3:342-6. 2010
    ....
  54. pmc Advanced glycation end products, oxidative stress and diabetic nephropathy
    Sho ichi Yamagishi
    Department of Pathophysiology and Therapeutics of Diabetic Vascular Complications, Kurume University School of Medicine, Kurume, Japan
    Oxid Med Cell Longev 3:101-8. 2010
    ..In this paper, we review the pathophysiological role of AGEs and their receptor (RAGE)-oxidative stress system in diabetic nephropathy...
  55. pmc Advanced glycation end products potentiate citrated plasma-evoked oxidative and inflammatory reactions in endothelial cells by up-regulating protease-activated receptor-1 expression
    Yuji Ishibashi
    Department of Pathophysiology and Therapeutics of Diabetic Vascular Complications, Kurume University School of Medicine, 67 Asahi Machi, Kurume 830 0011, Japan
    Cardiovasc Diabetol 13:60. 2014
    ..Blockade of the crosstalk between AGE-RAGE axis and coagulation system by rivaroxaban might be a novel therapeutic target for thromboembolic disorders in diabetes. ..
  56. pmc Relationship between advanced glycation end products and plaque progression in patients with acute coronary syndrome: the JAPAN-ACS sub-study
    Yoshifumi Fukushima
    Department of Cardiology, Juntendo University School of Medicine, Tokyo, Japan
    Cardiovasc Diabetol 12:5. 2013
    ..The present sub-study of JAPAN-ACS investigates the association between AGEs and RAGE, and PV...
  57. doi request reprint Role of advanced glycation end products (AGEs) and oxidative stress in vascular complications in diabetes
    Sho ichi Yamagishi
    Department of Pathophysiology, Kurume University School of Medicine, Kurume, Japan
    Biochim Biophys Acta 1820:663-71. 2012
    ..Over a course of days to weeks, early glycation products undergo further reactions such as rearrangements and dehydration to become irreversibly cross-linked, fluorescent protein derivatives termed advanced glycation end products (AGEs)...
  58. ncbi request reprint Role of advanced glycation end products (AGEs) in osteoporosis in diabetes
    Sho ichi Yamagishi
    Department of Pathophysiology and Therapeutics of Diabetic Vascular Complications, Kurume, Japan
    Curr Drug Targets 12:2096-102. 2011
    ..I also discuss here the potential therapeutic interventions of the AGEs-RAGE axis for preventing osteoporosis in diabetes...
  59. ncbi request reprint Role of advanced glycation end products (AGEs) and oxidative stress in diabetic retinopathy
    Sho ichi Yamagishi
    Department of Medicine, Kurume University School of Medicine, Kurume 830 0011, Japan
    Curr Pharm Des 14:962-8. 2008
    ....
  60. ncbi request reprint An improved anion-exchange high-performance liquid chromatography method for measuring oxidized form of LDLs in human plasma
    Soichi Kitano
    SRL Inc, Hino, Tokyo, Japan
    Ann Clin Biochem 47:460-6. 2010
    ..In this study, we developed a novel and convenient high-performance liquid chromatography (HPLC) method for measuring ox-LDL levels in humans...
  61. ncbi request reprint Kinetics, role and therapeutic implications of endogenous soluble form of receptor for advanced glycation end products (sRAGE) in diabetes
    Sho ichi Yamagishi
    Division of Cardiovascular Medicine, Department of Medicine, Kurume University School of Medicine, Kurume 830 0011, Japan
    Curr Drug Targets 8:1138-43. 2007
    ..We also discuss the possibility that endogenous sRAGE may be a therapeutic target for the prevention of diabetic vascular complications...
  62. doi request reprint Cardiovascular disease in recent onset diabetes mellitus
    Shoichi Yamagishi
    Department of Pathophysiology and Therapeutics of Diabetic Vascular Complications, Kurume University School of Medicine, Kurume 830 0011, Japan
    J Cardiol 57:257-62. 2011
    ..We also discuss here the potential therapeutic strategies that specially target the mechanisms responsible for vascular alterations in diabetes...
  63. ncbi request reprint Potential utility of telmisartan, an angiotensin II type 1 receptor blocker with peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-modulating activity for the treatment of cardiometabolic disorders
    Sho ichi Yamagishi
    Department of Medicine, Division of Cardiovascular Medicine, Kurume University School of Medicine, Kurume 830 0011, Japan
    Curr Mol Med 7:463-9. 2007
    ..In this paper, we reviewed the potential utility of telmisartan in insulin resistance and vascular complications in diabetes...
  64. ncbi request reprint Advanced glycation end products (AGEs), oxidative stress and diabetic retinopathy
    Sho ichi Yamagishi
    Department of Pathophysiology and Therapeutics of Diabetic Vascular Complications, Kurume University School of Medicine, Japan
    Curr Pharm Biotechnol 12:362-8. 2011
    ..Therefore, this article summarizes the role of AGEs and oxidative stress in diabetic retinopathy and discusses a potential utility of the blockade of this system by PEDF in this devastating disorder...
  65. doi request reprint Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetes
    Sho ichi Yamagishi
    Department of Pathophysiology and Therapeutics of Diabetic Vascular Complications, Kurume University School of Medicine, Kurume, Japan
    Exp Gerontol 46:217-24. 2011
    ..We also discuss here the potential utility of the restriction of food-derived AGEs in diabetic vascular complications...
  66. ncbi request reprint Pigment epithelium-derived factor (PEDF) inhibits angiotensin II-induced smooth muscle cell proliferation through its anti-oxidative properties
    Sho ichi Yamagishi
    Department of Medicine, Kurume University School of Medicine, 67 Asahi Machi, Kurume, Japan
    Protein Pept Lett 14:615-7. 2007
    ..Here, we show that PEDF inhibits angiotensin II-induced smooth muscle cell proliferation through its anti-oxidative properties. Our present study suggests that PEDF may play a protective role against atherosclerosis...
  67. doi request reprint Nitric oxide, a janus-faced therapeutic target for diabetic microangiopathy-Friend or foe?
    Sho ichi Yamagishi
    Department of Pathophysiology and Therapeutics of Diabetic Vascular Complications, Kurume University School of Medicine, Kurume 830 0011, Japan
    Pharmacol Res 64:187-94. 2011
    ..In this paper, we review the janus-faced aspects of NO in diabetic microangiopathy...
  68. ncbi request reprint Role of advanced glycation end products (AGEs) and their receptor (RAGE) in the pathogenesis of diabetic microangiopathy
    S Yamagishi
    Department of Internal Medicine III, Kurume University School of Medicine, 67 Asahi Machi, Kurume 830 0011, Japan
    Int J Clin Pharmacol Res 23:129-34. 2003
    ..Several types of AGE inhibitors and their therapeutic implications in diseases, including diabetic microangiopathy, will be discussed in the next review article...
  69. ncbi request reprint Pigment epithelium-derived factor (PEDF) prevents advanced glycation end products (AGEs)-elicited endothelial nitric oxide synthase (eNOS) reduction through its anti-oxidative properties
    Sho ichi Yamagishi
    Department of Medicine, Kurume University School of Medicine, 67 Asahi Machi, Kurume, Japan
    Protein Pept Lett 14:832-5. 2007
    ..Here, we show that PEDF prevents the AGEs-elicited eNOS reduction through its anti-oxidative properties. Our present study suggests that PEDF may also play a protective role against atherosclerosis...
  70. ncbi request reprint Serum level of advanced glycation end-products (AGEs) is an independent determinant of plasminogen activator inhibitor-1 (PAI-1) in nondiabetic general population
    S Yamagishi
    Department of Medicine, Division of Cardiovascular Medicine, Kurume University School of Medicine, Kurume, Japan
    Horm Metab Res 39:845-8. 2007
    ..The AGE-associated thrombogenic abnormality may be involved in atherogenesis in nondiabetic subjects...
  71. doi request reprint Inhibitors of advanced glycation end products (AGEs): potential utility for the treatment of cardiovascular disease
    Sho ichi Yamagishi
    Department of Medicine, Kurume University School of Medicine, Kurume, Japan
    Cardiovasc Ther 26:50-8. 2008
    ..Therefore, in this article, we review several agents with inhibitory effects on AGEs formation and their therapeutic implications in CVD in diabetes...
  72. ncbi request reprint Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complications
    Sho ichi Yamagishi
    Kurume University School of Medicine, Department of Pathophysiology and Therapeutics of Diabetic Vascular Complications, Kurume, 67 Asahi Machi, Kurume 830 0011, Japan
    Expert Opin Investig Drugs 17:983-96. 2008
    ....
  73. ncbi request reprint Clinical utility of acarbose, an alpha-glucosidase inhibitor in cardiometabolic disorders
    Sho ichi Yamagishi
    Department of Pathophysiology and Therapeutics of Diabetic Vascular Complications, Division of Nephrology, Kurume University School of Medicine, Kurume, Japan
    Curr Drug Metab 10:159-63. 2009
    ..In this paper, we review the clinical utility of acarbose in various cardiometabolic disorders...
  74. doi request reprint Possible involvement of tobacco-derived advanced glycation end products (AGEs) in an increased risk for developing cancers and cardiovascular disease in former smokers
    S Yamagishi
    Department of Medicine, Kurume University School of Medicine, 67 Asahi Machi, Kurume 830 0011, Japan
    Med Hypotheses 71:259-61. 2008
    ....
  75. doi request reprint Decreased high-density lipoprotein cholesterol level is an independent correlate of circulating tumor necrosis factor-alpha in a general population
    Sho ichi Yamagishi
    Department of Pathophysiology and Therapeutics of Diabetic Vascular Complications, Kurume University School of Medicine, Kurume, Japan
    Clin Cardiol 32:E29-32. 2009
    ..In this study, we examined the independent determinants of serum TNF-alpha levels in a Japanese general population...
  76. ncbi request reprint Receptor for advanced glycation end products (RAGE): a novel therapeutic target for diabetic vascular complication
    Sho ichi Yamagishi
    Division of Cardiovascular Medicine, Department of Medicine, Kurume University School of Medicine, Kurume 830 0011, Japan
    Curr Pharm Des 14:487-95. 2008
    ..In this review, we discuss several types of agents that could potentially inhibit RAGE expression or its downstream pathways and their therapeutic implications in diabetic vascular complication...
  77. ncbi request reprint Telmisartan, its potential therapeutic implications in cardiometabolic disorders
    Sho ichi Yamagishi
    Department of Internal Medicine III, Kurume University School of Medicine, Kurume 830 0011, Japan
    Recent Pat Cardiovasc Drug Discov 1:79-83. 2006
    ..In this review, we focused on telmisartan, and discussed its potential therapeutic implications in cardiometabolic disorders...
  78. ncbi request reprint Role of oxidative stress in the development of vascular injury and its therapeutic intervention by nifedipine
    Sho ichi Yamagishi
    Department of Medicine, Kurume University School of Medicine, Kurume 830 0011, Japan
    Curr Med Chem 15:172-7. 2008
    ..We further discuss the potential clinical utility of anti-oxidative properties of nifedipine on various cardiometabolic disorders...
  79. ncbi request reprint Regulation of advanced glycation end product (AGE)-receptor (RAGE) system by PPAR-gamma agonists and its implication in cardiovascular disease
    Sho ichi Yamagishi
    Department of Pathophysiology and Therapeutics of Diabetic Vascular Complications, Kurume University School of Medicine, 67 Asahi Machi, Kurume 830 0011, Japan
    Pharmacol Res 60:174-8. 2009
    ..Therefore, in this study, we review effects of PPARgamma agonists on the AGE-RAGE system and their implication in CVD...
  80. ncbi request reprint Pigment epithelium-derived factor inhibits vascular endothelial growth factor-induced vascular hyperpermeability both in vitro and in vivo
    S Yamagishi
    Department of Medicine, Kurume University School of Medicine, Japan
    J Int Med Res 35:896-9. 2007
    ....
  81. ncbi request reprint Smooth muscle cell pathophysiology and advanced glycation end products (AGEs)
    Sho ichi Yamagishi
    Department of Pathophysiology and Therapeutics of Diabetic Vascular Complications, Kurume University School of Medicine, Kurume, Japan
    Curr Drug Targets 11:875-81. 2010
    ....
  82. ncbi request reprint A possible involvement of crosstalk between advanced glycation end products (AGEs) and asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor in accelerated atherosclerosis in diabetes
    S Yamagishi
    Department of Medicine, Division of Cardiovascular Medicine, Kurume University School of Medicine, 67 Asahi Machi, Kurume 830 0011, Japan
    Med Hypotheses 69:922-4. 2007
    ....
  83. ncbi request reprint Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cells
    Sho ichi Yamagishi
    Division of Endocrinology and Metabolism, Department of Medicine, Kurume University School of Medicine, Kurume 830 0011, Japan
    J Biol Chem 277:20309-15. 2002
    ....
  84. ncbi request reprint Advanced glycation end products-induced apoptosis and overexpression of vascular endothelial growth factor in bovine retinal pericytes
    Sho ichi Yamagishi
    Division of Endocrinology and Metabolism, Kurume University School of Medicine, Kurume, 830 0011, Japan
    Biochem Biophys Res Commun 290:973-8. 2002
    ..These results suggest that AGEs disturbed retinal microvascular homeostasis by inducing pericyte apoptosis and VEGF overproduction and thus were involved in the pathogenesis of early phase diabetic retinopathy...
  85. ncbi request reprint Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy
    Sho ichi Yamagishi
    Department of Internal Medicine III, Kurume University School of Medicine, Japan
    Curr Pharm Des 11:2279-99. 2005
    ....
  86. ncbi request reprint Molecular mechanisms for vascular injury in the metabolic syndrome
    S Yamagishi
    Department of Internal Medicine III, Kurume University School of Medicine, Kurume, Japan
    Drugs Exp Clin Res 31:123-9. 2005
    ..We also discuss promising therapeutic strategies that specifically target the mechanisms responsible for vascular alterations in the metabolic syndrome...
  87. ncbi request reprint Angiotensin II augments advanced glycation end product-induced pericyte apoptosis through RAGE overexpression
    Sho ichi Yamagishi
    Department of Internal Medicine III, Kurume University School of Medicine, 67 Asahi Machi, Kurume 830 0011, Japan
    FEBS Lett 579:4265-70. 2005
    ..Further, AII augmented AGE-induced pericyte apoptosis, the earliest hallmark of diabetic retinopathy. Our present study may implicate a crosstalk between AGE-RAGE system and AII in diabetic retinopathy...
  88. ncbi request reprint Possible participation of advanced glycation end products in the pathogenesis of osteoporosis in diabetic patients
    S Yamagishi
    Department of Internal Medicine, Kurume University School of Medicine, 67 Asahi Machi, Kurume 830 0011, Japan
    Med Hypotheses 65:1013-5. 2005
    ....
  89. ncbi request reprint Protective role of pravastatin in the pathogenesis of the metabolic syndrome
    S Yamagishi
    Department of Medicine, Kurume University School of Medicine, 67 Asahi Machi, Kurume 830 0011, Japan
    Med Hypotheses 66:609-11. 2006
    ....
  90. ncbi request reprint Potential utility of statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in diabetic retinopathy
    S Yamagishi
    Department of Internal Medicine, Kurume University School of Medicine, Japan
    Med Hypotheses 66:1019-21. 2006
    ....
  91. ncbi request reprint Minodronate, a nitrogen-containing bisphosphonate, is a promising remedy for treating patients with diabetic retinopathy
    S Yamagishi
    Department of Internal Medicine, Kurume University School of Medicine, 67 Asahi Machi, Kurume 830 0011, Japan
    Med Hypotheses 66:273-5. 2006
    ....
  92. ncbi request reprint Pericyte biology and diseases
    S Yamagishi
    Department of Internal Medicine III, Kurume University School of Medicine, Japan
    Int J Tissue React 27:125-35. 2005
    ..In this study, we review the biology of pericytes and the pathological role of pericyte loss or dysfunction in various devastating disorders such as diabetic retinopathy, atherosclerosis and tumor angiogenesis..
  93. ncbi request reprint Acarbose is a promising therapeutic strategy for the treatment of patients with nonalcoholic steatohepatitis (NASH)
    S Yamagishi
    Department of Medicine, Kurume University School of Medicine, 67 Asahi Machi, Kurume 830 0011, Japan
    Med Hypotheses 65:377-9. 2005
    ....
  94. ncbi request reprint Blockade by nifedipine of advanced glycation end product-induced CD40-CD40 ligand interaction in endothelial cells
    S Yamagishi
    Department of Medicine, Kurume University School of Medicine, Kurume, Japan
    Drugs Exp Clin Res 31:221-6. 2005
    ..These results suggest that AGEs could enhance CD40-CD40L interaction, thereby promoting atherosclerosis in diabetes. Blockade of CD40-CD40L signaling in ECs may be a molecular target for the vasculoprotective property of nifedipine...
  95. ncbi request reprint Potential therapeutic implication of nifedipine, a dihydropyridine-based calcium antagonist, in advanced glycation end product (AGE)-related disorders
    S Yamagishi
    Department of Medicine, Kurume University School of Medicine, 67 Asahi Machi, Kurume 830 0011, Japan
    Med Hypotheses 65:392-4. 2005
    ....
  96. ncbi request reprint Pigment epithelium-derived factor (PEDF) promotes growth of pericytes through autocrine production of platelet-derived growth factor-B
    Sho ichi Yamagishi
    Department of Internal Medicine III, Kurume University School of Medicine, 67 Asahi Machi, Kurume 830 0011, Japan
    Microvasc Res 69:128-34. 2005
    ..Our present study suggests that PEDF could act as a mitogen or survival factor for pericytes, thereby being involved in the maintenance of retinal microvascular homeostasis...
  97. ncbi request reprint Possible participation of advanced glycation end products in the pathogenesis of colorectal cancer in diabetic patients
    S Yamagishi
    Department of Medicine, Kurume University School of Medicine, 67 Asahi Machi, Kurume 830 0011, Japan
    Med Hypotheses 64:1208-10. 2005
    ....
  98. pmc Palmitate-induced apoptosis of microvascular endothelial cells and pericytes
    Sho ichi Yamagishi
    Division of Endocrinology and Metabolism, Department of Medicine, Kurume University School of Medicine, Kurume, Japan
    Mol Med 8:179-84. 2002
    ..In this study, we investigated the influence of palmitate, a major saturated free fatty acid in plasma, on the apoptotic cell death of cultured microvascular endothelial cells (EC) and retinal pericytes...
  99. pmc Beraprost sodium, a prostaglandin I2 analogue, protects against advanced gycation end products-induced injury in cultured retinal pericytes
    Sho ichi Yamagishi
    Division of Endocrinology and Matabolism, Department of Medicine, Kurume University School of Medicine, Japan
    Mol Med 8:546-50. 2002
    ..In this study, we examined whether beraprost sodium can protect against AGE-induced cytotoxicity in cultured retinal pericytes...